At Biocon, we are driven by our passion to develop research-driven, cutting-edge biopharmaceuticals to address the relatively unmet needs of patients suffering from chronic diseases such as cancer, diabetes and autoimmune conditions.
Our commitment to impact global health has led us to build differentiated capabilities in the areas of biologics and complex small molecules. We have used advanced technology platforms to develop and deliver a rich portfolio of generic small molecule APIs and formulations, novel biologics and biosimilars including monoclonal antibodies, rh-Insulin and analogs.
We believe our value proposition built around differentiation and scale has enabled us to seek global leadership to provide access to affordable biopharmaceuticals for patients and partners across the globe.
We are constantly engaged in pursuit of excellence to develop high quality, safe and efficacious products that can heal the world.